Alzheimer's Disease and Related Disorders - Original Article

Journal of Neural Transmission

, 115:1181

First online:

Open Access This content is freely available online to anyone, anywhere at any time.

Intake of copper has no effect on cognition in patients with mild Alzheimer’s disease: a pilot phase 2 clinical trial

  • Holger KesslerAffiliated withDepartment of Psychiatry and Psychotherapy, Saarland University Hospital
  • , Thomas A. BayerAffiliated withDivision of Molecular Psychiatry, Department of Psychiatry and Psychotherapy, University of Göttingen Email author 
  • , Daniela BachAffiliated withDepartment of Psychiatry and Psychotherapy, Saarland University Hospital
  • , Thomas Schneider-AxmannAffiliated withDivision of Molecular Psychiatry, Department of Psychiatry and Psychotherapy, University of Göttingen
  • , Tillmann SupprianAffiliated withDepartment of Geriatric Psychiatry, Rheinische Kliniken Düsseldorf
  • , Wolfgang HerrmannAffiliated withCentral Laboratory, Department for Clinical Chemistry, Saarland University Hospital
  • , Manfred HaberAffiliated withCentral Pharmacy, Saarland University Hospital
  • , Gerd MulthaupAffiliated withInstitute for Chemistry and Biochemistry, Free University
  • , Peter FalkaiAffiliated withDivision of Molecular Psychiatry, Department of Psychiatry and Psychotherapy, University of Göttingen
    • , Frank-Gerald PajonkAffiliated withCenter for Psychiatric and Psychotherapeutic Care and Rehabilitation, Dr. K. Fontheim’s Hospital for Mental Health

Abstract

Disturbed copper (Cu) homeostasis may be associated with the pathological processes in Alzheimer’s disease (AD). In the present report, we evaluated the efficacy of oral Cu supplementation in the treatment of AD in a prospective, randomized, double-blind, placebo-controlled phase 2 clinical trial in patients with mild AD for 12 months. Sixty-eight subjects were randomized. The treatment was well-tolerated. There were however no significant differences in primary outcome measures (Alzheimer’s Disease Assessment Scale, Cognitive subscale, Mini Mental Status Examination) between the verum [Cu-(II)-orotate-dihydrate; 8 mg Cu daily] and the placebo group. Despite a number of findings supporting the hypothesis of environmental Cu modulating AD, our results demonstrate that oral Cu intake has neither a detrimental nor a promoting effect on the progression of AD.

Keywords

Cu Alzheimer Clinical trial ADAS-cog MMSE